Latest News

From GLP-1 Trial Results to the Follow-Up Visit

From GLP-1 Trial Results to the Follow-Up Visit

A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

read more

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

FDA Drug Approval Decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

read more
Clinical Trials Roundup | 31 July 2026

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

read more
The Security Blind Spot in Life Science Digitalization

The Security Blind Spot in Life Science Digitalization

The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...

read more
Making AI Work in a Regulated Medtech Industry

Making AI Work in a Regulated Medtech Industry

For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...

read more
Biotech IPO 2026: From Drought to Record-Breaking Deals

Biotech IPO 2026: From Drought to Record-Breaking Deals

The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...

read more
Want the FDA to Make Peptides More Accessible?

Want the FDA to Make Peptides More Accessible?

As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...

read more
Psychedelic Medicine Commercialization: Altered Perceptions

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

read more
FDA Drug Approval Decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

read more
Clinical Trials Roundup | 31 July 2026

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

read more
The Security Blind Spot in Life Science Digitalization

The Security Blind Spot in Life Science Digitalization

The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...

read more
Making AI Work in a Regulated Medtech Industry

Making AI Work in a Regulated Medtech Industry

For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...

read more
Biotech IPO 2026: From Drought to Record-Breaking Deals

Biotech IPO 2026: From Drought to Record-Breaking Deals

The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...

read more
Want the FDA to Make Peptides More Accessible?

Want the FDA to Make Peptides More Accessible?

As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...

read more
Psychedelic Medicine Commercialization: Altered Perceptions

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Safety, Toxicology, and Risk Assessment of Essential Oils

Safety, Toxicology, and Risk Assessment of Essential Oils

Essential oils are complex mixtures of volatile phytochemicals that have long been incorporated into traditional medicine, personal care products, aromatherapy, and topical therapeutic formulations. Their diverse biological activities—including antimicrobial,...

read more
Weekly News Roundup | 27 July 2026

Weekly News Roundup | 27 July 2026

Life science news 27 July 2026: GSK wins its first lung cancer approval with a selective ROS1 inhibitor, Lilly's triple agonist retatrutide delivers up to 22.6 per cent weight loss in two pivotal trials, and the MHRA clears what it calls the world's first lower-carbon...

read more
Clinical Trials Roundup | 24 July 2026

Clinical Trials Roundup | 24 July 2026

Merck's enlicitide receives FDA approval as the first oral PCSK9 inhibitor for adults with hypercholesterolaemia, GSK's zidesamtinib earns FDA approval as a next-generation ROS1 selective inhibitor for previously treated non-small cell lung cancer, GSK's camlipixant...

read more
The False Economy of Returning to Manual PGD Processes

The False Economy of Returning to Manual PGD Processes

Across healthcare, financial pressure is forcing difficult decisions. Pharmacy teams are being asked to do more with less. Service expansion, dealing with NHS patients, workforce shortages remain acute, and every investment is being scrutinised. In this environment,...

read more

Further News

Telix Buys ITM: Radioisotope Supply and a Manufacturing Test

Telix Pharmaceuticals has agreed to buy ITM Isotope Technologies Munich SE. Telix describes ITM as the largest supplier of lutetium-177 by revenue. The deal places that radioisotope supply business inside a therapeutics developer. Telix issued the joint announcement...

LNP Engineering for RNA Delivery: Beyond Encapsulation Efficiency

For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...

Closing the Gap: Why Where You Live Still Determines Your IBD Care

Inflammatory bowel disease (IBD) is no longer a rare disease in Australia. Close to 180,000 Australians are now living with Crohn’s disease or ulcerative colitis, with prevalence approaching 1% of the population in some estimates. Unlike many chronic diseases, IBD...

How GLP-1 Drugs Are Reshaping Anesthesia Practice

Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...

Designing Resilient Health Systems That Endure

The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...

Weekly News Roundup | 21 September 2026

Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...

Vivan Therapeutics and Ad Atomica Announce Discovery Collaboration

Partnership pairs Vivan's genotype resolved cancer screening data with Ad Atomica's AI driven molecule design platform LONDON, UK, 16 September 2026: Vivan Therapeutics and Ad Atomica today announced a discovery collaboration. Vivan tests thousands of drugs and drug...

Azetukalner NDA Filed as Xenon Pauses Depression Trials

Xenon filed the azetukalner NDA for focal seizures on 17 September, then paused depression trial enrolment over neuropsychiatric events.

    Metal Medical Device Quality Control: Why Dimensions Are Not Enough

    A correct dimension does not guarantee a safe device Metal device quality control should translate clinical and engineering risks into measurable attributes. A machined component can match its drawing, look clean and pass inspection while still carrying a material,...

    Healthcare Innovation Is Not Always About Something New

    Healthcare innovation is often associated with something new. A new technology. A new platform. A new device. A new digital service. But healthcare organizations do not always need to add something new to improve care. Sometimes, they need to change something that is...

    Clinical Trials Roundup | 18 Sept 2026

    Definium Therapeutics’ DT120 meets its primary endpoint in the Phase 3 Panorama study in generalised anxiety disorder, AstraZeneca’s camizestrant misses its primary endpoint in the Phase III SERENA-4 study in first-line breast cancer, Vera Therapeutics’ atacicept cuts...

    Trutakna Two-Year Data Sharpen the IgAN Full Approval Race

    Trutakna two-year ORIGIN 3 data put Vera in the IgAN full approval race. What was reported, what was left out, and where UK access stands.

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.